Muscle & Nerve · 1987 · 22 citations · 28 references
Life SciencesNeurologyNeuroscienceAutoimmunityNeuroimmunologyNeuropathologyAutoimmune Neurological DisordersDemyelinating DiseasesDemyelinating DisordersNervous System PathologyNeuroinflammationPeripheral Nerve InjuryAcute Inflammatory Demyelinating PolyneuropathyAutoimmune DemyelinationDemyelination PathophysiologyDemyelination ResponseGuillain-barré Syndrome PathogenesisImmune-mediated DemyelinationInflammatory DemyelinationPeripheral Nerve Demyelination
Serum from patients with acute inflammatory polyneuropathy (the Guillain-Barré syndrome, GBS) demyelinates peripheral nerves in vivo more intensely than control human serum. To clarify the processes leading to demyelination we injected rat sciatic nerves with serum from GBS and control subjects in the presence of complement and examined the sequential morphologic changes over 7 days. One day after injection, five of six GBS sera but none of seven control sera caused vesicular demyelination; 3-5 days after injection both GBS and control sera produced macrophage-mediated demyelination. These observations suggest that GBS serum can initiate acute myelin injury through a humoral mechanism that is disease associated. This response appears to be distinct from delayed cell-mediated serum-induced demyelination that is not disease specific.
28
Plasmapheresis and acute Guillain‐Barre syndrome
Neurology · 1985 · 772 citations
Pathology of the Guillain-Barr� syndrome
John W. Prineas · Annals of Neurology · 1981 · 246 citations
Life Sciences, Neurology, Pathology +17
Padmavathy Vanguri, Carol Lee Koski, B. W. Silverman et al. · Proceedings of the National Academy of Sciences · 1982 · 158 citations · Full text